MedTrace Logo

Supplementation With Alpha-lipoic Acid and Silybum Marianum(LUDLEV®) for the Improvement of Fatty Liver Disease

NCT05913986 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2023-06-22

No results posted yet for this study

Summary

This randomized, controlled, double-blind study evaluates the utility of alpha-lipoic acid and silybum marianum , versus placebo, in the treatment of metabolic associated fatty liver disease.

Conditions

  • Metabolic Associated Fatty Liver Disease

Interventions

DIETARY_SUPPLEMENT

LUDLEV®300 mg/46.2 mg

LUDLEV®300 mg/46.2 mg once day

OTHER

Placebo

Placebo treatment (maltodextrin), once daily (u.i.d)

Sponsors & Collaborators

  • Saluz Investigación S. C.

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-03-01
Primary Completion
2024-01-10
Completion
2024-03-30

Countries

  • Mexico

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05913986 on ClinicalTrials.gov